EconomyEli Lilly beats estimates, raises sales outlook as Zepbound and Mounjaro demand surges again
Eli Lilly said sales of its obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter. The company beat estimates and raised its sales outlook.
C
CNBC★★★☆☆2026-10-29 11:44Original
Eli Lilly beats estimates, raises sales outlook as Zepbound and Mounjaro demand surges again
Economy